Business Context and Reporting Period
Caris Life Sciences, Inc. (CAI), a Texas corporation, filed this Form 8-K on April 1, 2026, to report the entry into a new material definitive financing agreement. The company is an emerging growth company listed on The Nasdaq Stock Market LLC.
Key Financial Metrics and Debt Structure
The filing details a new senior secured credit facility with the following components:
- Initial Term Facility: $400 million funded on the Closing Date, maturing in April 2031.
- Delayed Draw Facility: Up to $300 million available through August 2027, restricted solely to Permitted Acquisitions.
- Incremental Facility: Uncommitted capacity up to $500 million.
- Interest Rates: Term SOFR + 5.00% or Base Rate + 4.00%.
- Liquidity Covenant: Maintenance of minimum qualified cash of $50 million tested quarterly.
- Collateral: First priority security interest in substantially all tangible and intangible personal property and subsidiary stock.
Material Changes Versus Prior Period
On the Closing Date, the company utilized proceeds from the Initial Term Facility to fully repay and terminate its previous credit agreement dated January 18, 2023. All guarantees, liens, and security interests associated with the previous agreement were terminated.
Outlook, Risks, and Covenants
The New Credit Agreement includes standard affirmative and negative covenants, including limitations on additional debt, liens, asset dispositions, and fundamental changes. Events of default include payment failures, covenant breaches, bankruptcy, and change of control, which could trigger acceleration of amounts due. The full text of the agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2026.
Investor Verification Checklist
- Verify the exact amount of outstanding debt under the previous credit agreement to confirm the full repayment status.
- Review the upcoming Form 10-Q for the full text of the New Credit Agreement to assess specific covenant definitions and restrictions.
- Monitor the company's quarterly cash balances to ensure compliance with the $50 million minimum qualified cash covenant.
- Assess the company's acquisition pipeline to determine the likelihood of drawing on the $300 million Delayed Draw Facility.